Retatrutide: Triple Agonist Research Map

People type retatrutide like they found the next pen after tirzepatide.

They found a research map for a three-receptor drug candidate.

Retatrutide is LY3437943. It is one engineered peptide built to hit three gut-hormone receptors at once. Those receptors are GIP, GLP-1, and glucagon. Semaglutide hits GLP-1. Tirzepatide hits GIP plus GLP-1. Retatrutide adds the glucagon receptor. Same gut-hormone neighborhood. Different lock count. Different approval status.

This page is the retatrutide research map. It sits next to tirzepatide vs semaglutide and peptides for weight loss. Compounds like AOD-9604 are a different lane. Start with Start Here if peptides are not day one. Stay here if you typed retatrutide, LY3437943, triple agonist, GLP-3, or “the one after tirzepatide.”

This is education. It is not medical advice. A three-receptor drug still in trials is not a reason to skip a clinician. A research-catalog cake is not a branded obesity pen.

What is retatrutide?

A peptide is a short chain of amino acids. Insulin is a peptide. Semaglutide is a peptide. Tirzepatide is a peptide. Retatrutide is a peptide. It was designed at Eli Lilly under the code LY3437943. It is still in development.

So what is retatrutide, in plain terms? A once-weekly injectable research molecule. It turns on three receptors tied to appetite, blood sugar handling, and energy-use talks:

• GIP — glucose-dependent insulinotropic polypeptide receptor
• GLP-1 — glucagon-like peptide-1 receptor
• Glucagon receptor — the third lock on this map

Analogy: think door locks. Semaglutide turns one lock. Tirzepatide turns two. Retatrutide asks what happens when you turn three. More locks is not the same as “already approved at the pharmacy.”

Retatrutide vs tirzepatide vs semaglutide

You do not need a hormone fellowship. You need three lanes and three jobs.

Lane	What it actually is	What the evidence talk is	What it is not
Semaglutide	GLP-1 receptor agonist. Brands: Ozempic, Wegovy	Large randomized programs. Head-to-head context on tirzepatide vs semaglutide	Not tirzepatide. Not retatrutide. Not a research-catalog fragment
Tirzepatide	Dual GIP + GLP-1 receptor agonist. Brands: Mounjaro, Zepbound	SURMOUNT programs versus placebo and versus semaglutide in approved-drug talks	Not retatrutide. Not a freeze-dried “upgrade” SKU
Retatrutide / LY3437943	Triple agonist at GIP, GLP-1, and glucagon receptors. Still in development	Phase 2 obesity and Phase 2 type 2 diabetes papers, plus discovery and later reviews	Not an FDA retail brand next to Zepbound
AOD-9604 / research fragments	Different mechanism neighborhood. Map on AOD-9604	Fragment research framing — not a triple-agonist trial file	Not retatrutide. Do not stack bottles because both say “weight”

You can be interested in all of them. You cannot mash semaglutide, tirzepatide, retatrutide, and a research fragment into one Reddit protocol and call the extra receptor a clinic result you bought with a coupon code.

Mechanism map

Search volume is not a protocol. A caption that says “tirzepatide but stronger” is not a protocol either.

Start with the receptors. Not the bottle.

• GLP-1 in one sentence: a gut hormone path tied to appetite, stomach emptying, and blood-sugar-linked insulin stories. Semaglutide was built to hit this lock.
• GIP in one sentence: a second gut-hormone receptor. Tirzepatide adds it beside GLP-1.
• Glucagon receptor in one sentence: the third lock on the retatrutide map. Discovery papers discuss it in energy-use and liver talks. It is not a free “burn fat” caption.

Why a triple agonist exists: Coskun and colleagues described LY3437943 as a new three-receptor drug candidate for blood-sugar control and weight-loss research endpoints. That 2022 Cell Metabolism paper is the classic discovery file. Honest explainers should open with it.

Here is the beginner translation of the clinical file.

Stop-you stat: a Phase 2 obesity trial of retatrutide in adults with obesity landed in the New England Journal of Medicine in 2023. Phase 2 answers dose, signal, and safety questions. It does not mint a retail label by itself.

Phase 2 type 2 diabetes: a 2023 Lancet trial tested retatrutide in people with type 2 diabetes. It used placebo and active comparators in that design. Diabetes endpoints and obesity endpoints are related talks. They are not the same shopping list.

Later map: later reviews put retatrutide on the pipeline next to approved one- and two-receptor drugs. A 2025 review summed efficacy and safety signals for retatrutide in obesity research. A 2026 Lancet paper extends the type 2 diabetes control talk. Reviews are maps. They are not marching orders.

Evidence limits, stated plainly:

• The discovery paper is real
• The Phase 2 obesity and diabetes papers are real
• Later reviews and follow-on clinical papers are real
• Retatrutide is still discussed as a drug candidate in development
• It is not an FDA-approved retail obesity or diabetes pen like Wegovy or Zepbound

This page refuses to invent citations. It refuses to crown a forum caption. It refuses to pretend a research-catalog “reta” cake is the Lilly trial product.

If you compete in sport, check the current banned list yourself. Trial-stage gut-hormone drugs and lookalike catalog chemicals are not a free pass because a shop URL said “research use only.”

Trial landscape at high level

Think in phases. Not captions.

• Discovery / early clinical: LY3437943 early science and first human bridging work sit in the 2022 Cell Metabolism file.
• Phase 2: Obesity and type 2 diabetes papers in 2023 built the public teaching file most people quote — often without reading the methods.
• Later development: Larger programs decide whether a molecule becomes a labeled medicine or does not.

I will not invent trial names, main endpoints, or approval dates that are not in the sources I cited. If a press release or forum says “already approved,” ask for the FDA label. Not a screenshot of a catalog.

Stomach side effects, dose steps, gallbladder and heart-rate talks, and who should never touch these drugs are clinician topics. This public page is the map. Not your chart.

Access lanes: approved Rx vs compounding vs research catalog

Three lanes. Keep them.

Labeled / approved drugs have an application, a label, a use, and manufacturing the agency inspects. Semaglutide and tirzepatide live there for obesity and diabetes uses today. Retatrutide does not inherit those stickers just because the receptor count went up.

Compounding is a pharmacy lane. A 503A pharmacy compounds for a patient with a prescription. That lane has its own FDA fights, shortage rules, and state-board oversight. A compounded script is still not a branded Phase 3 program.

Research catalogs sell named chemicals for research use. COA if you are lucky. “Not for human consumption” on the page. Forums treat that line as a wink. I do not. A research-use vial labeled retatrutide, reta, GLP-3, or triple regulator is a catalog SKU. It is not the Lilly trial product. It is not Wegovy. It is not Zepbound.

I am not going to tell you to buy a research chemical for human use. I am not going to tell you to skip a doctor. I am going to tell you to name the lane before you name the SKU.

Reconstitution notes

Formats differ. Branded pens are not mixed cakes. Research catalogs often sell freeze-dried vials. Compounding pharmacies dispense what the script says.

If a freeze-dried cake is even on the table, learn the math before you invent a protocol. How to reconstitute peptides covers bacteriostatic water, U-100 syringe ticks, and not wasting product on foam. Read the label on the object you hold. A pen is not a cake. A cake is not a retail prescription.

I will not dump a retatrutide mg-and-days schedule on a public page. That is Pro on purpose.

Who this page is for

Start with the question. Not the bottle.

This page is for you if you typed retatrutide, LY3437943, triple agonist, GLP-3, or “the one after Mounjaro” and want the research map before you spend money.

This page is not for you if you want a diagnosis for obesity, type 2 diabetes, fatty liver, or “broken metabolism” from a blog. Those are clinician talks. A trial-stage molecule and a research bottle do not replace that visit.

1. Read first. Name the lane before you name the SKU.
2. Name the chemistry. Retatrutide / LY3437943 is the triple agonist above. If the bottle says only “GLP-3,” ask what sequence and purity claim you are actually buying.
3. Do not crown the nickname. “Next Ozempic” won the caption. It did not mint an FDA retail label.
4. If a freeze-dried cake is on the table, learn the reconstitution math — then stop. Protocol depth lives in Peptides & Pump Pro.

Where I actually look when the job is a retatrutide-class research compound

Education first. You already got the map. This block is the labs I will put my name on, with the codes that fire. Research-use catalog pages only. Not a treatment claim. Not a “buy this to lose weight.” Not a claim that a catalog cake is the Lilly trial product.

Peptira lists a RETA-3 research presentation with code LEE. Paramount carries a Triple Regulator / GLP-3 R research presentation with tracking that fires LEE10. BioLongevity, Limitless, and S1 stay as home / shop chips for wider browsing. I am not inventing a live retatrutide card where the partner page is not cleanly available.

Research-catalog SKUs currently live on partner pages (not a treatment recommendation).

Peptira RETA-3 10 mg · LEEParamount Triple Regulator · LEE10BioLongevity home · LEE15Limitless home · LEE20S1 shop · LEE10

Match the product to the job. Do not collect bottles. Do not use a research catalog as a back door to a labeled obesity drug.

Frequently asked questions about retatrutide

Is retatrutide the same as tirzepatide?

No. Tirzepatide is dual GIP + GLP-1. Retatrutide adds the glucagon receptor. Different molecule. Different stage of development. Read the tirzepatide vs semaglutide map if two receptors versus one is your real question.

Is retatrutide FDA-approved for weight loss?

Not as a general retail obesity sticker this page is claiming. The public teaching file is Phase 2 plus later papers. Still-in-trials status is not a Wegovy or Zepbound label. Ask for the FDA label before you believe a caption.

Is a research-catalog “reta” or “GLP-3” the same as clinical-trial retatrutide?

No. A research-use chemical sold for lab research is not the Lilly trial product. It is not an approved branded pen. Name the lane.

How is retatrutide different from AOD-9604?

Different job. Retatrutide is a three-receptor gut-hormone story. AOD-9604 is a fragment-style metabolic research compound on a different map. Start on AOD-9604 and the peptides for weight loss hub if that is the lane you meant.

Can I just run a retatrutide protocol from a forum?

You can do a lot of unwise things. I would not. Name the chemical. Name whether you are holding a research catalog, a compounded script, or a fantasy about a labeled pen. Protocol depth lives in Pro on purpose.

Sources & Further Reading

Verified starting points. Classic discovery plus Phase 2 primaries and newer reviews. Not a protocol. Not a drug label. Not an endorsement to self-treat.

• LY3437943 triple agonist discovery-to-clinic, 2022 — PubMed 35985340
• Phase 2 obesity trial, NEJM 2023 — PubMed 37366315
• Phase 2 type 2 diabetes trial, Lancet 2023 — PubMed 37385280
• GLP-1 medicines for T2D and obesity review, 2024 — PubMed 38843460
• GLP-1 agonists and polyagonists for weight loss update, 2024 — PubMed 39305981
• Retatrutide for obesity treatment research review, 2025 — PubMed 40291085
• Type 2 diabetes inadequate-control paper, Lancet 2026 — PubMed 42250575

Read primary sources. Do not treat a PubMed ID as a shopping list.

The bottom line

Retatrutide is a triple agonist. LY3437943 in the naming trail. It hits GIP, GLP-1, and glucagon receptors. Real target talk. Real Phase 2 file. Still a medicine in development on the public research map. Not a casual retail twin of tirzepatide or semaglutide.

It is not tirzepatide. It is not semaglutide. It is not AOD-9604. Keep the lanes. Read the papers. Do not buy a research cake because a caption told you it was the next FDA pen.

If you need the beginner on-ramp, use Start Here and what are peptides. Reconstitution math lives on how to reconstitute peptides. Adjacent reading: tirzepatide vs semaglutide, peptides for weight loss, and AOD-9604.

I built Peptides & Pump so you can get this without a guru tax. If you want the protocol library, member discussions, and a place to think out loud before you spend money, that is Pro. If you are not ready to pay, use the free Knowledge Base first. Then come back and argue with me when you have read more than a caption.

---

Supplier footnote: Research suppliers I mention when people ask about retatrutide-class research compounds: Peptira RETA-3 10 mg (code LEE) and Paramount Triple Regulator / GLP-3 R (code LEE10). Browse wider catalogs via BioLongevity home (code LEE15), Limitless home (code LEE20), and S1 shop (code LEE10). Match the product to the job. Do not collect bottles. A research catalog is not a labeled obesity drug.

Disclaimer. This article is for educational and research purposes only. It is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Retatrutide, LY3437943, triple agonists, GLP-3 research presentations, and related research-catalog presentations are not presented here as treatments for obesity, type 2 diabetes, fatty liver, aging, metabolic syndrome, or any other condition. A medicine still in development is not automatically an FDA-approved retail drug. A research-catalog product is not a compounded prescription and is not a labeled obesity or diabetes drug. Always consult a qualified healthcare provider before starting any peptide, drug, supplement, or protocol, especially if you have a medical condition or take prescription medication. Peptides & Pump does not sell peptides.

Affiliate disclosure. Some links on this page are affiliate links. If you buy through them, I may earn a commission at no extra cost to you. Codes LEE15, LEE20, LEE, and LEE10 are the ones I actually use where a coupon fires. That commission is how I keep publishing free education. I only link suppliers I am willing to put my name on.